The 5 most overpaid CEOs in healthcare ranked

Healthcare companies have become some of the largest businesses in the U.S. and worldwide, with the sector expected to grow to roughly 20% of the U.S. GDP by 2027. Leaders of these companies have also seen their salaries explode over the last several years as well as other compensation from stocks and bonuses.

With such high earners in the sector, As You Sow decided to rank the 100 most overpaid CEOs across all sectors­­––and included several healthcare names to know.

Here are the top 5 overpaid healthcare CEOs ranked:

Joseph Hogan, CEO of medical device company Align Technologies

  • Total payment: $41,758,338
  • Overpayment: $27,119,793
  • Median worker pay: $13,180

Stephen MacMillan, chairman, president and CEO of medical technology company Hologic

  • Total payment: $42,020,142
  • Overpayment: $29,140,855
  • Median worker pay: $87,845

Michael Neidorff, CEO of Centene

  • Total payment: $26,122,414
  • Overpayment: $12,561,836
  • Median worker pay: $66,021

Alex Gorsky, CEO of Johnson & Johnson

  • Total payment: $20,097,572
  • Overpayment: $7,551,949
  • Median worker pay: $75,000

Kent Thiry, CEO of Davita

  • Total payment: $32,017,501
  • Overpayment: $20,477,984
  • Median worker pay: $60,889

See the full list here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.